Lixte Biotechnology (LIXT) said Thursday it closed a registered direct offering of 434,784 shares at $2.415 apiece for about $1.1 million in gross proceeds.
The biotechnology company said it plans to use the net proceeds for working capital and other general corporate purposes.
Lixte also said it issued unregistered warrants in a concurrent private placement to acquire up to 434,784 shares, with each warrant exercisable at $2.29 per share.
Shares were down 2.4% in recent trading.
Price: 1.66, Change: -0.04, Percent Change: -2.35
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.